NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) Short Interest Update

NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) saw a large decline in short interest in April. As of April 15th, there was short interest totalling 51,900 shares, a decline of 16.2% from the March 31st total of 61,900 shares. Approximately 2.6% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,290,000 shares, the short-interest ratio is presently 0.0 days.

NeuroBo Pharmaceuticals Trading Up 2.6 %

NASDAQ NRBO opened at $3.14 on Friday. NeuroBo Pharmaceuticals has a 12 month low of $2.89 and a 12 month high of $6.75. The company’s 50 day simple moving average is $4.43 and its 200 day simple moving average is $3.97.

About NeuroBo Pharmaceuticals

NeuroBo Pharmaceuticals, Inc, a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity.